|
|
Article: Vicor Technologies Issued Australian Patent for Altered State Physiology Drug Development Platform.
- Article from:
- Obesity & Diabetes Week
- Article date:
- November 16, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), announced that on July 23, 2009, the Australian Patent Office issued it a Deed of Letters Patent for its altered state physiology drug development platform Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i[R] nonlinear algorithm and software to stratify patients at risk of sudden cardiac death and trauma victims in need of lifesaving intervention. Vicor also has filed several patents associated with the development of peptides and proteins derived from "state-dependent" physiologies to ...
Related newspaper, magazine, and journal articles:
|
|
Article: Vicor Technologies Announces Receipt of 510(k) ...
Biotech Week;
January 21, 2009 ;
700+ words
... ... Fater, President and CEO of Vicor Technologies, Inc., announced that on December 29, 2008 Vicor Technologies received FDA 510(k) approval ... commercialization of the technology. Vicor Technologies, Inc. (OTCBB: VCRT) is ...
|
|